Doylestown, PA, United States of America

Kirk L Sorgi

This inventor holds 20 USPTO granted patents, plus 2 CIPO patents and 2 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Janssen Pharmaceutica Nv, Ortho-Mcneil Pharmaceutical Corp., Mcneil Ab. Active years: 1989-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kirk L Sorgi. Retrieved from https://idiyas.com/inventor/kirk-l-sorgi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 20

% Patents Active = 45.0

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 6)

Average Co-Inventor Count = 6.2

ph-index = 7

Forward Citations = 96(Granted Patents)

Location History:

Norristown, PA (US) (1989 - 1990)
Blue Bell, PA (US) (1995 - 1999)
Buckingham, PA (US) (2008 - 2013)
Doylestown, PA (US) (1999 - 2016)

Company Filing History:

11 out of 2,103

Janssen Pharmaceutica Nv

patents

4 out of 363

Ortho-Mcneil Pharmaceutical Corp.

Oxis International, Inc.

patents

5. 1 out of 834,708

Other

patents

Years Active: 1989-2016

Loading Chart...

Areas of Expertise:

Pyrimidine Derivatives

Phosphonic Acid Compounds

Anticonvulsant Derivatives

Piperazinyl Benzamide

Diazepanyl Benzamide

Quaternary Salt Compounds

GnRH Peptides

Stereoselective Reactions

Hexahydro Isoquinolines

Topiramate Immunoassay

Sulfamate Derivatives

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9359327 - Process for the preparation of substituted pyrimidine derivatives (2016-06-07),

2. 9079884 - Process for the preparation of substituted pyrimidine derivatives (2015-07-14),

3. 9079883 - Process for the preparation of substituted pyrimidine derivatives (2015-07-14),

4. 9079882 - Process for the preparation of substituted pyrimidine derivatives (2015-07-14),

5. 8680273 - Process for the preparation of piperazinyl and diazepanyl benzamide derivatives (2014-03-25),

6. 8497373 - Phosphonic acid compounds as inhibitors of serine proteases (2013-07-30),

7. 8394804 - Phosphonic acid compounds as inhibitors of serine proteases (2013-03-12),

8. 8309720 - Process for the preparation of substituted pyrimidine derivatives (2012-11-13),

9. 8278446 - Process for preparing substituted diaminopyrimidine oximes (2012-10-02),

10. 8168829 - Synthesis of quaternary salt compounds (2012-05-01),

11. 7893257 - Process for the preparation of piperazinyl and diazepanyl benzamide derivatives (2011-02-22),

12. 7459461 - Phosphonic acid compounds as inhibitors of serine proteases (2008-12-02),

13. 7060725 - Substituted sulfamate anticonvulsant derivatives (2006-06-13),

14. 6515130 - Process for preparing [S-(R*,S*)]-&bgr;-[[[1-[1-oxo-3(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-3-pyridinepropanoic acid and derivatives (2003-02-04),

15. 6235876 - Liquid phase process for the preparation of GNRH peptides (2001-05-22),

Title: Innovator Spotlight: Kirk L. Sorgi

Introduction: Kirk L. Sorgi, based in Doylestown, PA, is an accomplished inventor known for his notable contributions to the pharmaceutical industry. With a total of 20 patents, he has focused on the synthesis of crucial compounds that serve as intermediates in drug development, particularly within the realm of histamine H-receptor modulators.

Latest Patents: Among his latest inventions are processes for the preparation of substituted pyrimidine derivatives. These processes are significant as they provide intermediate compounds essential for the synthesis of histamine H-receptor modulators, which can play a crucial role in various therapeutic applications. The innovations presented in these patents demonstrate the potential for advancements in the treatment of different health conditions through targeted pharmacological methods.

Career Highlights: Kirk has held influential positions at reputable companies such as Janssen Pharmaceutica and Ortho-McNeil Pharmaceutical Corporation. His experiences at these organizations have equipped him with extensive knowledge and expertise in drug development and synthetic chemistry, allowing him to contribute significantly to the field. His inventive work continues to influence the pharmaceutical landscape, demonstrating a profound understanding of both scientific and practical aspects of innovation.

Collaborations: Throughout his career, Kirk has collaborated with notable colleagues, including David C. Palmer and Sergio Cesco-Cancian. These partnerships have fostered a rich environment of creativity and innovation, leading to the successful development of new pharmaceutical processes and compounds.

Conclusion: Kirk L. Sorgi's prolific career as an inventor has made a meaningful impact in the pharmaceutical industry. With his innovative processes and collaborative spirit, he exemplifies the essence of modern invention, continuing to pave the way for advancements in medicine. As he develops new methodologies, the future looks promising for his contributions to drug synthesis and therapeutic development.

Profile summary based on public USPTO records.